SE9900190D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9900190D0
SE9900190D0 SE9900190A SE9900190A SE9900190D0 SE 9900190 D0 SE9900190 D0 SE 9900190D0 SE 9900190 A SE9900190 A SE 9900190A SE 9900190 A SE9900190 A SE 9900190A SE 9900190 D0 SE9900190 D0 SE 9900190D0
Authority
SE
Sweden
Prior art keywords
new compounds
enantiomer
compound
formula
active compounds
Prior art date
Application number
SE9900190A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Daniel Sohn
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9900190A priority Critical patent/SE9900190D0/xx
Publication of SE9900190D0 publication Critical patent/SE9900190D0/xx
Priority to DZ000004A priority patent/DZ3002A1/fr
Priority to JP2000594794A priority patent/JP2002535320A/ja
Priority to PL00349775A priority patent/PL349775A1/xx
Priority to CZ20012643A priority patent/CZ20012643A3/cs
Priority to AU23374/00A priority patent/AU778674B2/en
Priority to EEP200100381A priority patent/EE200100381A/xx
Priority to KR1020017009056A priority patent/KR20010101585A/ko
Priority to UA2001085896A priority patent/UA69438C2/uk
Priority to CNB008030103A priority patent/CN1188405C/zh
Priority to SK1022-2001A priority patent/SK10222001A3/sk
Priority to NZ512684A priority patent/NZ512684A/xx
Priority to IL14444400A priority patent/IL144444A0/xx
Priority to CA002359105A priority patent/CA2359105A1/fr
Priority to RU2001123433A priority patent/RU2237668C2/ru
Priority to BR0007577-9A priority patent/BR0007577A/pt
Priority to IDW00200101578A priority patent/ID30556A/id
Priority to EP00902246A priority patent/EP1149083A1/fr
Priority to HU0200412A priority patent/HUP0200412A3/hu
Priority to PCT/SE2000/000079 priority patent/WO2000043378A1/fr
Priority to TR2001/02087T priority patent/TR200102087T2/xx
Priority to ARP000100215A priority patent/AR030145A1/es
Priority to MYPI20000180A priority patent/MY133438A/en
Priority to TNTNSN00015A priority patent/TNSN00015A1/fr
Priority to US09/621,387 priority patent/US6291458B1/en
Priority to ZA200105491A priority patent/ZA200105491B/en
Priority to IS6007A priority patent/IS6007A/is
Priority to NO20013601A priority patent/NO20013601L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9900190A 1997-07-02 1999-01-22 New compounds SE9900190D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE9900190A SE9900190D0 (sv) 1999-01-22 1999-01-22 New compounds
DZ000004A DZ3002A1 (fr) 1999-01-22 2000-01-09 Nouveaux sels de morpholinobenzamide.
TR2001/02087T TR200102087T2 (tr) 1999-01-22 2000-01-14 Yeni morfolinbenzamid tuzları
IL14444400A IL144444A0 (en) 1999-01-22 2000-01-14 New morpholinobenzamide salts
BR0007577-9A BR0007577A (pt) 1999-01-22 2000-01-14 Sal farmaceuticamente aceitável do composto, formulação farmacêutica, uso de um sal ou solvato, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, vasoespasmo e controle de crescimento de tumores e para preparação do sal do composto
CZ20012643A CZ20012643A3 (cs) 1999-01-22 2000-01-14 Nové morfolinobenzamidové soli
AU23374/00A AU778674B2 (en) 1999-01-22 2000-01-14 New morpholinobenzamide salts
EEP200100381A EE200100381A (et) 1999-01-22 2000-01-14 Morfolinobensamiidi uued soolad
KR1020017009056A KR20010101585A (ko) 1999-01-22 2000-01-14 신규 모르폴리노벤즈아미드 염
UA2001085896A UA69438C2 (en) 1999-01-22 2000-01-14 Morpholine benzamide salts
CNB008030103A CN1188405C (zh) 1999-01-22 2000-01-14 新的吗啉代苯甲酰胺盐
SK1022-2001A SK10222001A3 (sk) 1999-01-22 2000-01-14 Morfolinobenzamidové soli
NZ512684A NZ512684A (en) 1999-01-22 2000-01-14 Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders
JP2000594794A JP2002535320A (ja) 1999-01-22 2000-01-14 新規なモルホリノベンズアミド塩
CA002359105A CA2359105A1 (fr) 1999-01-22 2000-01-14 Nouveau sels morpholinobenzamides
RU2001123433A RU2237668C2 (ru) 1999-01-22 2000-01-14 Новые соли морфолинобензамида, способ их получения, фармацевтическая композиция на их основе и способ лечения
PL00349775A PL349775A1 (en) 1999-01-22 2000-01-14 New morpholinobenzamide salts
IDW00200101578A ID30556A (id) 1999-01-22 2000-01-14 Garam-garam morfolinobenzamida baru
EP00902246A EP1149083A1 (fr) 1999-01-22 2000-01-14 Sels morpholinobenzamides
HU0200412A HUP0200412A3 (en) 1999-01-22 2000-01-14 New morpholinobenzamide salts, process for their preparation and pharmaceutical compositions containing them and their use
PCT/SE2000/000079 WO2000043378A1 (fr) 1999-01-22 2000-01-14 Nouveau sels morpholinobenzamides
ARP000100215A AR030145A1 (es) 1999-01-22 2000-01-18 Sal farmaceuticamente aceptable de morfolinobenzamida o solvato de la misma, formulacion farmaceutica que la contiene, su uso para la fabricacion de un medicamento y proceso para la preparacion de dicha sal o solvato
MYPI20000180A MY133438A (en) 1999-01-22 2000-01-20 Morpholinobenzamide salts
TNTNSN00015A TNSN00015A1 (fr) 1999-01-22 2000-01-20 Nouveaux sels de morpholinobenzamide
US09/621,387 US6291458B1 (en) 1997-07-02 2000-07-21 Morpholinobenzamide salts
ZA200105491A ZA200105491B (en) 1999-01-22 2001-07-03 New morpholinobenzamide salts.
IS6007A IS6007A (is) 1999-01-22 2001-07-17 Ný morfólínóbensamíðsölt
NO20013601A NO20013601L (no) 1999-01-22 2001-07-20 Nye morfolinobenzamidsalter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900190A SE9900190D0 (sv) 1999-01-22 1999-01-22 New compounds

Publications (1)

Publication Number Publication Date
SE9900190D0 true SE9900190D0 (sv) 1999-01-22

Family

ID=20414186

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900190A SE9900190D0 (sv) 1997-07-02 1999-01-22 New compounds

Country Status (28)

Country Link
US (1) US6291458B1 (fr)
EP (1) EP1149083A1 (fr)
JP (1) JP2002535320A (fr)
KR (1) KR20010101585A (fr)
CN (1) CN1188405C (fr)
AR (1) AR030145A1 (fr)
AU (1) AU778674B2 (fr)
BR (1) BR0007577A (fr)
CA (1) CA2359105A1 (fr)
CZ (1) CZ20012643A3 (fr)
DZ (1) DZ3002A1 (fr)
EE (1) EE200100381A (fr)
HU (1) HUP0200412A3 (fr)
ID (1) ID30556A (fr)
IL (1) IL144444A0 (fr)
IS (1) IS6007A (fr)
MY (1) MY133438A (fr)
NO (1) NO20013601L (fr)
NZ (1) NZ512684A (fr)
PL (1) PL349775A1 (fr)
RU (1) RU2237668C2 (fr)
SE (1) SE9900190D0 (fr)
SK (1) SK10222001A3 (fr)
TN (1) TNSN00015A1 (fr)
TR (1) TR200102087T2 (fr)
UA (1) UA69438C2 (fr)
WO (1) WO2000043378A1 (fr)
ZA (1) ZA200105491B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR055424A1 (es) 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
RU2540464C2 (ru) * 2012-05-28 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Водорастворимое производное амида салициловой кислоты, обладающее транквилизирующей, ноотропной и анальгезирующей активностью
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds

Also Published As

Publication number Publication date
NO20013601L (no) 2001-09-11
ID30556A (id) 2001-12-20
CZ20012643A3 (cs) 2002-01-16
IS6007A (is) 2001-07-17
RU2237668C2 (ru) 2004-10-10
WO2000043378A1 (fr) 2000-07-27
ZA200105491B (en) 2002-10-03
AR030145A1 (es) 2003-08-13
AU778674B2 (en) 2004-12-16
US6291458B1 (en) 2001-09-18
JP2002535320A (ja) 2002-10-22
CN1337956A (zh) 2002-02-27
EP1149083A1 (fr) 2001-10-31
PL349775A1 (en) 2002-09-09
HUP0200412A2 (en) 2002-06-29
NO20013601D0 (no) 2001-07-20
IL144444A0 (en) 2002-05-23
DZ3002A1 (fr) 2004-03-27
KR20010101585A (ko) 2001-11-14
SK10222001A3 (sk) 2002-03-05
TNSN00015A1 (fr) 2005-11-10
BR0007577A (pt) 2001-10-23
HUP0200412A3 (en) 2002-11-28
EE200100381A (et) 2002-12-16
UA69438C2 (en) 2004-09-15
NZ512684A (en) 2003-06-30
TR200102087T2 (tr) 2001-12-21
MY133438A (en) 2007-11-30
CN1188405C (zh) 2005-02-09
AU2337400A (en) 2000-08-07
CA2359105A1 (fr) 2000-07-27

Similar Documents

Publication Publication Date Title
SE9904508D0 (sv) New compounds
SE0200979D0 (sv) New compounds
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
TW200745111A (en) New compounds
SE0202462D0 (sv) Novel use
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
SE0104334D0 (sv) Therapeutic agents
SE0104340D0 (sv) New compounds
TW200606164A (en) New compounds
SE0100569D0 (sv) New compounds
SE9901573D0 (sv) New compounds
AU3850600A (en) Dalda analogs and their use
SE0102440D0 (sv) New compound
SE9903997D0 (sv) New compounds
SE0102055D0 (sv) New Compounds
TW200800984A (en) New compounds
SE9904507D0 (sv) New compounds
IL152337A0 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
SE0002476D0 (sv) New compounds
EA200600866A1 (ru) Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний
EP1019047A4 (fr) Agents antithrombotiques
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
SE9900190D0 (sv) New compounds
SE9901572D0 (sv) New compounds
SE0102057D0 (sv) New Salts I